Neurological Disorder Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

A neurological disorder is characterized by dysfunction in any part of the brain or nervous system, resulting in physical and/or psychological symptoms. Congenital neurological diseases are those that appear during the early years of embryo development and can be diagnosed at birth. Acquired neurological disorders, on the other hand, develop after birth as a result of traumatic brain injuries, immune disorders, postnatal injections, spinal cord injuries, neoplasm, and exposure to environmental chemicals or toxins, among other things.

The neurological Disorder Drugs Market is expected to experience exponential growth in demand in the neurological disorder drugs market. Because large pharmaceutical companies are exiting the neurology space, small biotech companies are stepping up to introduce new neurology drugs. However, neuroscience clinical trials are expensive, and the success rate is much lower than in other disease indications. As a result, companies should identify new genes that lead to new drug delivery pathways for Neurological Disorder Drugs Market. Apart from North America, companies should invest in Asia Pacific because the region is expected to grow exponentially during the forecast period. Money flow in the field of CNS is one of the key drivers contributing to market growth.

Epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular diseases, and other neurology disorders are examples. Anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and other drug classes are used to treat neurology disorders. The rise in the prevalence of neurology diseases among the global geriatric population can be attributed to the growth of the global Neurological Disorder Drugs Market.

Key Players

Amgen Inc., UCB S.A., Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Otsuka America Pharmaceutical, Inc., AstraZeneca plc, and Novartis International AG are among the key players